
    
      Enteral formula administration designed for critically ill patients in metabolic stress
      situations, hyperglycemia and insulin resistance, formulated with monounsaturated fatty acids
      (MUFA), slowly absorption carbohydrates, omega-3 series polyunsaturated fatty acids
      (PUFA)enriched in eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), should be
      associated with an improvement in metabolic control, based on glucose levels reduction, and a
      decrease of insulin resistance infectious complications , mechanical ventilation days, ICU
      and hospital stay. All this against other two high protein conventional specific diets for
      hyperglycaemia patients.
    
  